Literature DB >> 11724849

Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.

M A Pfaller1, S A Messer, K Mills, A Bolmström, R N Jones.   

Abstract

The performance of the Etest for testing the susceptibilities to caspofungin (MK-0991) of 726 isolates of Candida spp. was assessed against the National Committee for Clinical Laboratory Standards (NCCLS) microdilution broth method. The NCCLS method employed RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35 degrees C. MICs were determined by Etest for all 726 isolates with RPMI agar containing 2% glucose (RPG) and were read after incubation for 48 h at 35 degrees C. The Candida isolates included Candida albicans (n = 486), Candida glabrata (n = 96), Candida tropicalis (n = 51), Candida parapsilosis (n = 47), Candida krusei (n = 11), Candida lusitaniae (n = 2), and Candida guilliermondii (n = 33). In addition, a subset of 314 isolates were also tested by Etest using Casitone agar (CAS) and antibiotic medium 3 agar (AM3). The Etest results obtained using RPG correlated well with reference MICs. Overall agreement was 94% with RPG, 82% with CAS, and 79% with AM3. When RPG was used, agreement ranged from 79% for C. parapsilosis to 100% for C. krusei, C. lusitaniae, and C. guilliermondii. When CAS was used, agreement ranged from 0% for C. lusitaniae to 100% for C. glabrata. With AM3, agreement ranged from 0% for C. lusitaniae to 100% for C. guilliermondii. All three media supported growth of each of the Candida species. Etest results were easy to read, with sharp zones of inhibition. In most instances (75%) where a discrepancy was observed between the Etest and the reference method, the Etest MIC was lower. The Etest method using RPG appears to be useful for determining caspofungin susceptibilities of Candida species.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724849      PMCID: PMC88553          DOI: 10.1128/JCM.39.12.4387-4389.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.

Authors:  P W Nelson; M Lozano-Chiu; J H Rex
Journal:  J Med Vet Mycol       Date:  1997 Jul-Aug

2.  Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds.

Authors:  A Szekely; E M Johnson; D W Warnock
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

3.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

Authors:  M Lozano-Chiu; V L Paetznick; M A Ghannoum; J H Rex
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

5.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 6.  Antifungal susceptibility testing: progress and future developments.

Authors:  M A Pfaller
Journal:  Braz J Infect Dis       Date:  2000-04       Impact factor: 1.949

7.  Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Houston; K Mills; A Bolmstrom; R N Jones
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

8.  Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.

Authors:  F Marco; M A Pfaller; S A Messer; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1998-09       Impact factor: 2.803

9.  Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B.

Authors:  M A Pfaller; S A Messer; A Bolmström
Journal:  Diagn Microbiol Infect Dis       Date:  1998-11       Impact factor: 2.803

10.  In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; G V Doern; M E Brandt; R A Hajjeh
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more
  26 in total

1.  Drug resistance is not directly affected by mating type locus zygosity in Candida albicans.

Authors:  Claude Pujol; Shawn A Messer; Michael Pfaller; David R Soll
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance.

Authors:  Peter M Silver; Brian G Oliver; Theodore C White
Journal:  Med Mycol       Date:  2008-05       Impact factor: 4.076

4.  In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.

Authors:  J B Pfaller; S A Messer; R J Hollis; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.

Authors:  M J Maxwell; S A Messer; R J Hollis; L Boyken; S Tendolkar; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

6.  Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.

Authors:  A Espinel-Ingroff; M Arendrup; E Cantón; S Cordoba; E Dannaoui; J García-Rodríguez; G M Gonzalez; N P Govender; E Martin-Mazuelos; M Lackner; C Lass-Flörl; M J Linares Sicilia; M A Rodriguez-Iglesias; T Pelaez; R K Shields; G Garcia-Effron; J Guinea; M Sanguinetti; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 7.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

Review 8.  Biology of the pathogenic yeast Candida glabrata.

Authors:  A Bialková; J Subík
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

9.  Candida guilliermondii fungemia in patients with hematologic malignancies.

Authors:  Corrado Girmenia; Giampaolo Pizzarelli; Francesco Cristini; Francesco Barchiesi; Elisabetta Spreghini; Giorgio Scalise; Pietro Martino
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

10.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.